Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   16:47
111,84 USD (-0,29%)
(-0,29%)   16:47
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. in het nieuws

10 september 2024 · Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference · Persbericht

28 augustus 2024 · Neurocrine Biosciences to Participate at Investor Conferences in September · Persbericht

28 augustus 2024 · Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia · Persbericht

7 augustus 2024 · Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference · Persbericht

1 augustus 2024 · Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance · Persbericht

18 juli 2024 · Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing · Persbericht

11 juli 2024 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results · Persbericht

1 juli 2024 · Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH · Persbericht

3 juni 2024 · Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 · Persbericht

3 juni 2024 · Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Kevin Gorman

Werknemers: 1.252

Aandelen Neurocrine Biosciences, Inc.

Beurswaarde: 12,50 miljard USD

Effecten: 100,98 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,40

Mijn selecties